Novo Nordisk (NVO) said Thursday that the US Food and Drug Administration has approved Alhemo (concizumab-mtci) as a once-daily prophylaxis to prevent or reduce the frequency of bleeding in adults and children above 12 years with hemophilia A or B without inhibitors.
The approval is based on the results of a phase 3 trial which showed that Alhemo cut the annualized bleeding rate by 79% in hemophilia B patients and by 86% in hemophilia A patients compared with no prophylaxis, the company said.
The approval offers patients in this population a subcutaneous injection option expanding on the drug's earlier approval in December 2024 for use in patients with hemophilia A or B with inhibitors, Novo Nordisk said.
Shares of Novo Nordisk were up 2% in early Friday trading.
Price: 48.10, Change: +1.03, Percent Change: +2.19
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。